Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
Go back to Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 30.38 +0.09 (0.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.29 | 52 Week High | $5.17 | |||
| Open | $30.49 | 52 Week Low | $0.94 | |||
| Day High | $31.60 | P/E | N/A | |||
| Day Low | $30.16 | EPS | $0.00 | |||
| Volume | 3,395,662 | |||||
